重组人血管内皮抑素联合多西紫杉醇和顺铂治疗晚期非小细胞肺癌的临床观察

目的观察重组人血管内皮抑素(恩度)联合多西紫杉醇和顺铂方案(TP)治疗晚期非小细胞肺癌(NSCLC)的近期临床疗效和毒副反应。方法经病理学证实的98例ⅢB～Ⅳ期NSCLC患者随机分为试验组52例,对照组46例,试验组接受恩度联合多西紫杉醇和顺铂方案治疗,对照组单用多西紫杉醇和顺铂方案化疗,用药1周期后评价毒副反应,至少完成2周期治疗后评价疗效。结果试验组有效率为50.0%,临床受益率为78.8%;对照组的有效率为30.4%,临床受益率为58.7%,差异有统计学意义(P<0.05)。毒副反应主要有白细胞减少、血小板减少、恶心、呕吐,肝功损害和肌肉关节痛等,两组比较差异无统计学意义(P>0.05)。结论恩度联合多西紫杉醇和顺铂方案一线治疗晚期NSCLC近期疗效优于单用多西紫杉醇和顺铂方案治疗,且未增加化疗的毒副反应,安全性较好,值得临床推广使用和进一步深入观察。

Observation of endostar combined with docetaxel and cisplatin for non-small cell lung cancer

Objective To observe the shortterm efficacy and safety of rhendostain（endostar） combined with Docetaxel and Cisplatin（TP regiment） in the treatment of advanced non-small cell lung cancer（NSCLC）.Methods A total of 98 patients,pathologically confirmed with ⅢB-Ⅳ NSCLC,were randomly divided as trial group（Endostar combined with Docetaxel and Cisplatin,n=52） and the control group（Docetaxel and Cisplatin,n=46）.All cases were evaluated after 2 courses at least and safety was evaluated after one course.Results The effective rate was 50.0%,and clinically beneficial rate was 78.8% in the trial group.The effective rate was 30.4%,and clinically beneficial rate was 58.7% in the contral group.There were significant differences（P0.05）.Side effects were neutropenia,thrombocytopenia,nausea,vomiting,liver function injury,muscular soreness,et al.There was no significant differences between the two groups（P0.05）.Conclusions Endostar combined docetaxel and cisplatin as the first line on advanced non-small cell lung cancer is more effective than Docetaxel and cisplatin,but without increazing side effects and with a good safety.It deserves to popularize and use in clinical and make futher close observation.